| 7.575 -0.965 (-11.3%) | 01-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 10.65 |
1-year : | 11.84 |
| Resists | First : | 9.12 |
Second : | 10.14 |
| Pivot price | 8.24 |
|||
| Supports | First : | 7.48 |
Second : | 6.22 |
| MAs | MA(5) : | 8.22 |
MA(20) : | 8.28 |
| MA(100) : | 7.33  |
MA(250) : | 5.76 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 57.7 |
D(3) : | 63.1 |
| RSI | RSI(14): 39.2 |
|||
| 52-week | High : | 10.41 | Low : | 3.19 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ DMAC ] has closed below the lower bollinger band by 10.6%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 31.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 8.63 - 8.69 | 8.69 - 8.73 |
| Low: | 7.39 - 7.44 | 7.44 - 7.48 |
| Close: | 7.5 - 7.58 | 7.58 - 7.65 |
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Fri, 16 Jan 2026
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Thu, 18 Dec 2025
Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation - simplywall.st
Thu, 18 Dec 2025
DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA - Business Wire
Thu, 13 Nov 2025
Earnings call transcript: DiaMedica Therapeutics Q3 2025 sees steady cash, R&D focus - Investing.com
Tue, 04 Nov 2025
With 48% ownership, insiders at DiaMedica Therapeutics Inc. (NASDAQ:DMAC) are pretty optimistic and have been buying recently - Yahoo Finance
Fri, 05 Sep 2025
Clinical-Stage Biotech DiaMedica to Showcase Preeclampsia and Stroke Programs at Major Conferences - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 52 (M) |
| Shares Float | 23 (M) |
| Held by Insiders | 26.2 (%) |
| Held by Institutions | 45.1 (%) |
| Shares Short | 5,300 (K) |
| Shares Short P.Month | 5,000 (K) |
| EPS | -0.71 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.99 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -38.4 % |
| Return on Equity (ttm) | -64.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.65 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -28 (M) |
| Levered Free Cash Flow | -17 (M) |
| PE Ratio | -10.67 |
| PEG Ratio | 0 |
| Price to Book value | 7.65 |
| Price to Sales | 0 |
| Price to Cash Flow | -14.23 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|